Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Depreciation & Amortization (CF) (2024 - 2026)

Beta Bionics recorded quarterly Depreciation & Amortization (CF) of $600000.0 in Q1 2026, little changed quarter-over-quarter from $600000.0 in Q4 2025, and up 98.02% year-over-year from $303000.0 in Q1 2025.

Beta Bionics' Depreciation & Amortization (CF) history runs 3 years deep, the most recent figure standing at $600000.0 for Q1 2026.

  • In Q1 2026, Depreciation & Amortization (CF) rose 98.02% year-over-year to $600000.0; the TTM figure through Mar 2026 stood at $1.9 million (up 62.55% YoY), while the FY2025 annual figure was $1.6 million, up 39.01% from the prior year.
  • Depreciation & Amortization (CF) came in at $600000.0 for Q1 2026 at Beta Bionics, roughly flat from $600000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $600000.0 in Q4 2025 to a low of $251000.0 in Q4 2024.
  • A 3-year average of $372333.3 and a median of $313000.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
  • On a YoY basis, Depreciation & Amortization (CF) climbed as much as 139.04% in 2025 and fell as far as 5.57% in 2025.
  • Beta Bionics' Depreciation & Amortization (CF) stood at $251000.0 in 2024, then surged by 139.04% to $600000.0 in 2025, then changed by 0.0% to $600000.0 in 2026.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $600000.0, $600000.0, and $350000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation & Amortization (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 381.00 Mn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 120.00 Mn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn 749.00 Mn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn 351.00 Mn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn 40.90 Mn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn 67.10 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 78.00 Mn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 123.40 Mn
10 Beta Bionics 572.34 Mn 542.03 Mn 16.44 Mn 600,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 600,000.00
Mar 31, 2026 600,000.00
Dec 31, 2025 600,000.00
Dec 31, 2025 600,000.00
Sep 30, 2025 350,000.00
Sep 30, 2025 350,000.00
Jun 30, 2025 347,000.00
Jun 30, 2025 347,000.00
Mar 31, 2025 303,000.00
Mar 31, 2025 303,000.00
Dec 31, 2024 251,000.00
Dec 31, 2024 251,000.00
Sep 30, 2024 300,000.00
Sep 30, 2024 300,000.00
Jun 30, 2024 313,000.00
Jun 30, 2024 313,000.00
Mar 31, 2024 287,000.00
Mar 31, 2024 287,000.00